

Policy: MP278

Section: Medical Benefit Policy

Subject: Hyperthermia in Cancer Therapy (e.g., HIPEC)

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Hyperthermia in Cancer Therapy (e.g., HIPEC)

II. Purpose/Objective:

To provide a policy of coverage regarding Hyperthermia in Cancer Therapy (e.g., HIPEC)

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking

into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

DESCRIPTION:

According to the National Cancer Institute, research has shown that high temperature can damage and kill cancer cells usually with minimal injury to normal tissues. The treatment may also cause shrinkage of the tumor since the treatment kills cancer cells and damages protein within the cells. Hyperthermia is almost always used with other forms of cancer therapy, such as radiation therapy and chemotherapy. The goal of hyperthermia in cancer therapy is to produce tumor tissue temperatures above 41 degrees centigrade.

INDICATIONS:

1. Local or regional external hyperthermia when used in combination with radiation therapy may be considered medically necessary for the treatment of any of the following:
 - a) primary or metastatic cutaneous or subcutaneous superficial tumors (lesions less than 3 cm from the surface); or
 - b) Superficial recurrent melanoma (lesions less than 3 cm from the surface); or,
 - c) locally advanced/recurrent breast cancer; or
 - d) cervical lymph node metastases from head and neck cancer.
2. Regional hyperthermic melphalan isolated limb perfusion is considered to be medically necessary in individuals with Stage II and IIIA extremity melanoma
3. **HIPEC:** Hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery is considered medically necessary for the following indications in individuals meeting the following criteria:
 - a) A diagnosis of:
 - pseudomyxoma peritonei (PMP), or
 - peritoneal carcinomatosis from colorectal cancer; or
 - diffuse malignant peritoneal mesothelioma
 - b) no extraperitoneal disease spread, and
 - c) a good performance status, and
 - d) who can be predicted to achieve complete surgical cytoreduction,
4. HIPEC with cisplatin at the time of interval debulking surgery for stage III ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
5. Microwave, or radiofrequency ablation is considered medically necessary for members with primary and/or metastatic liver malignancies who are not candidates for open surgical resection when the following criteria are met:
 - a. Diagnosis of hepatic metastases from a colorectal primary cancer or a hepatocellular cancer; and
 - b. Isolated liver disease. and
 - c. Medical documentation based on pre-operative imaging to support a reasonable expectation that all tumors in the liver would be potentially destroyed; and
 - d. Medical documentation that the members is an unacceptable open surgical candidate because of:
 - i. the location or extent of the liver disease; or
 - ii. co-morbid conditions such that the member is unable to tolerate an open surgical resection; and
 - e. Medical documentation showing that liver lesions are 4 cm or less in diameter and occupy less than 50 % of the liver parenchyma.

LIMITATIONS:

Members with nodal or extra-hepatic systemic metastases are not considered candidates for microwave or radiofrequency ablation.

EXCLUSIONS:

Local or regional external hyperthermia when used in combination with radiation therapy in lesions greater than 3 cm from the surface is considered experimental, investigational or unproven.

Local hyperthermia is considered experimental, investigational or unproven when used alone or in combination with chemotherapy.

Whole body hyperthermia therapy is considered experimental, investigational or unproven for all indications.

Hyperthermia in combination with radiation therapy for the treatment of chest wall recurrence of breast cancer is considered experimental, investigational or unproven due of insufficient evidence regarding its effectiveness in this condition.

Hyperthermia in combination with radiation therapy for the treatment of locally advanced prostate cancer is considered experimental, investigational or unproven due of insufficient evidence regarding its effectiveness in this condition.

Hyperthermic intrapleural chemotherapy for the treatment of intrapleural mesothelioma is considered to be experimental, investigational or unproven due of insufficient evidence regarding its effectiveness in this condition.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH: Hyperthermia in Cancer Therapy

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements

77600 Hyperthermia, externally generated, superficial

77605 Hyperthermia, externally generated, deep

77610 Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators

77615 Hyperthermia generated by interstitial probe(s); more than 5 interstitial applicators

77620 Hyperthermia generated by intracavitary probe(s)

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supercede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. *Ann Surg Oncol.* 1999;6(8):727-731.

National Institute for Clinical Excellence (NICE). Complete cytoreduction and heated intraoperative intraperitoneal chemotherapy (Sugarbaker technique) for peritoneal carcinomatosis. *Interventional Procedure Guidance 116.* London, UK: NICE; March 2005. Available at: <http://www.nice.org.uk/nicemedia/pdf/ip/IPG116guidance.pdf>

National Institute for Clinical Excellence. Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). *Interventional Procedure Guidance 56.* London, UK: NICE; April 2004. Available at: <http://www.nice.org.uk/nicemedia/pdf/IPG056guidance.pdf>.

Stewart JH 4th, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: Current status and future directions. *Ann Surg Oncol.* 2005;12(10):765-777

National Coverage Determination (NCD) for Hyperthermia for Treatment of Cancer (110.1)

Cioppa T, Vaira M, Bing C, D'Amico S, Bruscano A, De Simone M. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei. *World J Gastroenterol.* 2008 Nov 28;14(44):6817-23.

National Cancer Institute (NCI). Hyperthermia in cancer treatments: Fact sheet. Revised Aug 2011.

<http://www.cancer.gov/cancertopics/factsheet/Therapy/hyperthermia>

Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. *J Clin Oncol*. 2009 Dec 20;27(36):6237-42.

Yan TD, Welch L, Black D, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. *Ann Oncol*. 2007a May;18(5):827-34.

Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FAN. Survival Analysis of Pseudomyxoma Peritonei Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg*. 2007 Jan;245(1):104-9

Levine EA, Stewart JH, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Experience with 501 Procedures. *J Am Coll Surg*. 2007 May;204(5):943-53.

Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. *Cancer*. 2010 Dec 15;116(24):5608-18

Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. *Ann Surg*. 2010 May;251(5):896-901.

Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH; Peritoneal Surface Oncology Group. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. *Br J Surg*. 2011 Jan;98(1):60-4.

Uptodate. Malignant peritoneal mesothelioma: Treatment Aug. 2012

UptoDate. Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities. June 2013.

UptoDate. Management of locoregional recurrence of breast cancer after mastectomy. June 2013.

Hurwitz, MD, Hansen, JL, et al. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153. *Cancer*. 2011;117(3):510-516.

Yun BL, Lee JM, Baek JH, et al. Radiofrequency ablation for treating liver metastases from a non-colorectal origin. *Korean J Radiol*. 2011; 12(5):579-587.

Zhang X, Chen B, Hu S, et al. Microwave ablation with cooled-tip electrode for liver cancer: an analysis of 160 cases. *Hepatogastroenterology*. 2008; 55(88):2184-2187.

Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. *J Clin Oncol*. 2005; 23(7):1358-1364.

Bleicher RF, Allegra DP, Nora DT, et al. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. *Ann Surg Oncol*. 2003; 10(1):52-58.

Lermite E, Lebigot J, Oberti F, et al. Radiofrequency thermal ablation of liver carcinoma. Prospective study of 82 lesions. *Gastroenterol Clin Biol*. 2006; 30(1):130-135

Morimoto M, Numata K, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. *World J Gastroenterol*. 2007; 13(7):1003-1009.

Martin RCG, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. *Annals Surg Onc*. 2010;17:171-178.

Votanopoulos KI, Swett K, Blackham AU et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer. *Ann Surg Onc*. 2013;20:1088-1092

Liu L, Zhang N, Min J, et al. Retrospective analysis on the safety of 5,759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC). *Oncotarget*. 2016;7(16):21570-21578.

van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. *NEJM* 2018; 378:230-240

National Comprehensive Cancer Network (NCCN). Colon cancer. NCCN Clinical Practice Guidelines in Oncology. V2.2023

National Comprehensive Cancer Network (NCCN). Malignant pleural mesothelioma. NCCN Clinical Practice Guidelines in Oncology. V1.2023

Madsen AH, Ladekarl M, Villadsen GE, et al. Effects of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Goblet Cell Carcinoma: A Prospective Cohort Study. *Ann Surg Oncol*. 2018;25(2):422-430.

van der Horst A, Versteijne E, Besselink MGH, et al. The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. *Int J Hyperthermia*. 2018;34(7):969-979

Brenkman HJF, Paeva M, van Hillegersberg R, et al. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer - A systematic review. *J Clin Med*. 2019;8(10).

National Comprehensive Cancer Network (NCCN). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. NCCN Clinical Practice Guidelines in Oncology. V2.2023

van der Kaaij RT, Wassenaar ECE, Koemans WJ, et al. Treatment of PERitoneal disease in Stomach Cancer with cytoreductive surgery and hyperthermic intraPERitoneal chemotherapy: PERISCOPE I initial results. *Br J Surg*. 2020;107(11):1520-1528

Chen V, Jones M, Cohen L, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: A systematic review. *Pleura Peritoneum*. 2022;7(4):159-167.

Polderdijk MCE, Brouwer M, Haverkamp L, et al. Outcomes of combined peritoneal and local treatment for patients with peritoneal and limited liver metastases of colorectal origin: A systematic review and meta-analysis. *Ann Surg Oncol*. 2022;29(3):1952-1962.

Wong LCK, Li Z, Fan Q, et al. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal sarcomatosis -- A systematic review and meta-analysis. *Eur J Surg Oncol*. 2022;48(3):640-648

This policy will be revised as necessary and reviewed no less than annually.

Devised: 9/20/2013

Revised: 9/20 (add ovarian cancer indication)

Reviewed: 10/14; 9/15, 10/16; 9/17, 9/18, 9/19, 9/21, 9/22, 9/23

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health

Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.